SCHEMBL6030337

SCHEMBL6030337

CCCCCCCCOC(=O)Nc1sc(CCCCCCC)c(C)c1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44
ALDH1A1 P00352 5/20 0.42
TSHR P16473 4/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPK1 P28482 2/20 0.42
MAPT P10636 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
GAA P10253 1/20 0.38
EPHX1 P07099 1/20 0.38
PKM P14618 1/20 0.38
ACHE P22303 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030952 1.00 CNR1 (0.44) CNR1CNR2ALDH1A1TSHRHSD17B10
SCHEMBL6030718 0.86 PKM (0.52) ALDH1A1TSHRHSD17B10MAPK1MAPT
SCHEMBL6030376 0.86 PKM (0.52) ALDH1A1TSHRHSD17B10MAPK1MAPT
SCHEMBL6031543 0.85 ALDH1A1 (0.45) CNR1CNR2ALDH1A1TSHRHSD17B10
SCHEMBL6029929 0.85 ALDH1A1 (0.45) CNR1CNR2ALDH1A1TSHRHSD17B10
SCHEMBL6029667 0.79 ALDH1A1 (0.40) ALDH1A1TSHRHSD17B10MAPK1MAPT
SCHEMBL6030380 0.79 PKM (0.43) ALDH1A1TSHRHSD17B10MAPK1MAPT
SCHEMBL6030720 0.79 PKM (0.43) ALDH1A1TSHRHSD17B10MAPK1MAPT
SCHEMBL6030976 0.79 PKM (0.47) ALDH1A1TSHRHSD17B10MAPK1MAPT
SCHEMBL6030676 0.77 PKM (0.47) ALDH1A1TSHRHSD17B10MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL CNR1 150/4885CNR2 559/4885ALDH1A1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.